-+ 0.00%
-+ 0.00%
-+ 0.00%

COGENT BIOSCIENCES INC - BEZUCLASTINIB TRIAL SHOWED 89% OF PATIENTS ACHIEVING ≥50% REDUCTION IN BONE MARROW MAST CELLS

路透·12/08/2025 12:31:24

登錄查看新聞詳情